Comprehensive Longevity Stack Research: Epithalon, GHK-Cu, NAD+, BPC-157

The Hallmarks of Aging: A Research Framework

Lopez-Otin et al.'s landmark 2013 paper (updated 2023) defined the hallmarks of aging as:

• Genomic instability
• Telomere attrition
• Epigenetic alterations
• Loss of proteostasis
• Disabled macroautophagy
• Deregulated nutrient sensing
• Mitochondrial dysfunction
• Cellular senescence
• Stem cell exhaustion
• Altered intercellular communication
• Chronic inflammation (inflammaging)
• Dysbiosis

No single peptide addresses all hallmarks. The rationale for multi-agent longevity research is covering the largest number of mechanistically distinct hallmarks with the smallest agent count. This guide addresses a 4-agent protocol covering hallmarks 2, 3, 4, 7, 8, 10, and 11.

The Four-Agent Protocol

Agent 1: Epithalon 50mg

Hallmarks addressed: Telomere attrition (#2), epigenetic alterations (#3), altered intercellular communication (#10)

Epithalon is the only research peptide with published evidence for direct telomerase activation in somatic cells. Its transcriptional mechanism (hTERT promoter activity, DNA methylation changes) places it squarely in hallmarks 2 and 3. Melatonin restoration addresses intercellular signaling via circadian/pineal axis.

Agent 2: GHK-Cu 50mg

Hallmarks addressed: Loss of proteostasis (#4), cellular senescence (#8), chronic inflammation (#11)

GHK-Cu's 300+ gene network includes chaperone upregulation (proteostasis), SASP reduction (anti-senescence), and comprehensive anti-inflammatory gene modulation.

Agent 3: NAD+ 500mg

Hallmarks addressed: Mitochondrial dysfunction (#7), deregulated nutrient sensing (#6), genomic instability (#1)

NAD+ restoration via supplementation restores sirtuin activity (SIRT1-7), which regulates mitochondrial biogenesis (PGC-1alpha), insulin sensitivity (FOXO/mTOR signaling), and DNA repair capacity (PARP support).

Agent 4: BPC-157 10mg

Hallmarks addressed: Chronic inflammation (#11), altered intercellular communication (#10), stem cell exhaustion (#9)

BPC-157's NO system modulation and growth factor receptor upregulation supports tissue homeostasis, reduces systemic inflammation through gut-barrier protection, and supports stem cell niche maintenance.

Hallmark Coverage Map

Hallmark

Epithalon

GHK-Cu

NAD+

BPC-157

Telomere attrition	Direct	--	SIRT1/chromatin	--
Epigenetic alterations	Direct	Partial	SIRT1	--
Loss of proteostasis	--	Chaperones	SIRT2	--
Mitochondrial dysfunction	Indirect	Indirect	Direct	--
Cellular senescence	Partial	Direct	SIRT1/p53	--
Intercellular communication	Melatonin	SASP reduction	--	NO/VEGF
Chronic inflammation	IL-6/TNF-alpha	NF-kB, IL-6	CD38/PARP	iNOS/NF-kB

Coverage: 9 of 12 hallmarks with at least one agent

Research Protocol Design

Sequencing Rationale

Phase 1 (Baseline establishment): 4 weeks with no treatment. Establish baseline telomere length, NAD+/NADH ratio, senescence markers, inflammatory cytokines.

Phase 2 (NAD+ restoration): Weeks 1-4 of treatment. NAD+ first to establish improved cellular energy state.

Phase 3 (Add Epithalon): Weeks 5-14 (10-day course). Transcriptional effects require cellular energy — pre-loading NAD+ may improve hTERT response.

Phase 4 (Add GHK-Cu): Weeks 15-24. ECM and anti-inflammatory effects become most relevant after initial genomic stabilization.

Phase 5 (Add BPC-157): Ongoing from week 10. Gut homeostasis benefits accumulate continuously.

Endpoint Battery for Full-Stack Research

Genomic/Telomere:

• Telomere length (RTL qPCR)
• hTERT expression (RT-qPCR)
• gamma-H2AX foci (DNA damage marker)

Metabolic/Mitochondrial:

• NAD+/NADH ratio (enzymatic assay)
• SIRT1 deacetylase activity
• Mitochondrial membrane potential (JC-1)
• ATP production rate

Inflammation/Senescence:

• IL-6, IL-8, TNF-alpha, MCP-1 (multiplex ELISA)
• p16INK4a, p21 expression
• SA-beta-galactosidase staining

ECM/Tissue:

• Collagen I/III ratio
• MMP-1, MMP-3, TIMP-1 expression

All four agents available from Apollo Peptide Sciences — for laboratory research only.